Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype

European Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 107-112

  Qiao, Hai Ling ^a   Hu, Yu Rong ^a   Tian, Xin ^a   Jia, Lin Jing ^a   Gao, Na ^a   Zhang, Li Rong ^a   Guo, Yu Zhong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

CYP2C19 genotype; Lansoprazole; Omeprazole; Pharmacokinetics; Proton pump inhibitor; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONCENTRATION PROCESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CROSS-OVER STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTON PUMPS;

EID: 33645402136     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0063-1     Document Type: Article

References (33)

1. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37:597-604
2. Pichard L, Pedrosa RC, Bonfils C et al (1995) Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47:410-418
3. VandenBranden M, Ring BJ, Binkley Sn, Wrighton SA (1996) Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6:81-91
4. Chiba N (1997), Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 11:66B-73B
5. Kahrilas PJ (2000) Strategies for medical management of reflux disease. Best Pract Res Clin Gastroenterol 14:775-791
6. Vigneri S, Termini R, Leandro G (1995) comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106-1110
7. Dent J, Yeomans ND, Mackinnon M (1994) Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 35:90-598
8. Klinkenberg-Knol EC, Festen HP, Jansen JB (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121:161-167
9. Hu YM, Xu JM, Mei Q, Xu XH, Xu SY (2005) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol Sin 26:384-388
10. Sugimoto M, Furuta T, Shirai N et al. (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76:290-301
11. Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH (2003) Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 23:711-719
12. Ieiri I, Kishimoto Y, Okochi H et al ?(2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492
13. Shu Y, Zhou HH (2000) Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 21:193-199
14. Bertilsson L, Lou YQ, Du YL et al (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of deb risoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397
15. Edeki TI, Goldstein JA, de Morais SMF et al (1996) Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics 6:357-360
16. de Morais SMF, Wilkinson GR, Blaisdell J (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
17. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598
18. Ieri I, Kubota T, Urae A et al (1996) Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59:647-653
19. Tanigawara Y, Aoyama N, Kita T et al (1999) CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 66:528-534
20. Ando T, Kato H, Sugimoto N et al (2005) A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci 50:1625-1631
21. Itagaki F, Homma M, Yuzawa K et al (2004) Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 56:1055-1059
22. Lee SB, Park SJ, Ryu JK et al (2003) Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. KorJ Gastroenterol 42:468-475
23. Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johnson EF, Waterman MR (ed) Methods in enzymology, vol 272: cytochrome P450. Academic, New York pp 210-218
24. Yuen KH, Choy WP, Tan HY (2001) Improved high performance liquid chromatographic analysis of omeprazole in human plasma. J Pharm Biomed Anal 2001:715-720
25. Karol MD, Granneman GR, Alexander K (1995) Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr B 668:182-186
26. Asuda S, Ohnishi A, Ogawa T et al (1994) Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 32:466-471
27. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T (2004) Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5:181-202
28. Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468
29. Meyer UA (2004) Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669-676
30. Yasuda S, Horai Y, Tomono Y et al (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58:143-154
31. Sugimoto M, Furuta T, Shirai N et al. (2005) Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 77:302-311
32. Horn J (2004) Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther 20:11-19
33. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492